Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SELECT TOXICOLOGY LAB (STL), LLC

NPI: 1952790206 · MANNING, SC 29102 · Clinical Medical Laboratory · NPI assigned 01/09/2015

$8.72M
Total Medicaid Paid
453,774
Total Claims
250,063
Beneficiaries
55
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialWADDINGTON, BILL (PRESIDENT)
NPI Enumeration Date01/09/2015

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 146,787 $2.90M
2019 147,300 $2.05M
2020 98,525 $1.13M
2021 26,370 $1.04M
2022 13,803 $642K
2023 11,729 $373K
2024 9,260 $596K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 34,787 17,416 $2.80M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 61,624 31,075 $2.10M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 12,162 6,393 $1.02M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 6,631 4,597 $482K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 3,674 2,577 $129K
80346 12,456 6,981 $116K
80363 12,278 6,859 $113K
80361 12,568 7,035 $112K
80371 12,273 6,887 $101K
80350 12,277 6,887 $100K
80337 11,220 6,268 $96K
80334 11,001 6,123 $95K
80368 11,059 6,136 $95K
80323 6,967 3,648 $85K
80325 6,971 3,614 $83K
80369 6,976 3,625 $82K
80345 12,317 6,882 $79K
80359 12,337 6,904 $79K
80320 5,903 2,918 $78K
80355 11,268 6,345 $76K
80356 12,447 6,983 $70K
80353 12,588 7,090 $66K
80348 14,825 8,090 $59K
80354 12,524 7,000 $59K
80349 13,273 7,393 $59K
80372 12,271 6,862 $59K
80373 12,307 6,896 $59K
80365 12,374 6,937 $59K
83992 12,337 6,903 $57K
80358 12,295 6,873 $57K
80367 11,078 6,156 $56K
80366 11,032 6,154 $55K
81025 3,474 2,521 $21K
80324 5,769 3,553 $18K
80375 5,295 3,242 $17K
80370 4,644 2,872 $15K
80360 5,300 3,243 $15K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 82 69 $1K
84443 Thyroid stimulating hormone (TSH) 144 117 $1K
87522 Neg quan hep c or qual rna 94 82 $954.46
80053 Comprehensive metabolic panel 148 126 $879.77
86803 86 73 $671.74
85025 Blood count; complete (CBC), automated, and automated differential WBC count 137 115 $585.44
87340 104 83 $528.91
84403 27 25 $413.07
86705 63 52 $388.65
82105 20 19 $215.28
80362 1,922 1,086 $211.47
84270 15 13 $166.61
86707 19 19 $165.17
86709 21 18 $121.32
80332 123 66 $92.19
36415 Collection of venous blood by venipuncture 142 121 $83.85
86592 33 29 $77.84
83735 12 12 $48.30